wikimedia
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
Graphs
1
Q26824877-C73DA2A4-4B5F-4753-A5AB-A0431CCEA5DD
Q26824877-C73DA2A4-4B5F-4753-A5AB-A0431CCEA5DD
BestRank
Statement
http://www.wikidata.org/entity/statement/Q26824877-C73DA2A4-4B5F-4753-A5AB-A0431CCEA5DD
Combating acquired resistance to tyrosine kinase inhibitors in lung cancer
P2860
Q26824877-C73DA2A4-4B5F-4753-A5AB-A0431CCEA5DD
BestRank
Statement
http://www.wikidata.org/entity/statement/Q26824877-C73DA2A4-4B5F-4753-A5AB-A0431CCEA5DD
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
42c65b12c9bd94822fdcc7295d2aa8615bd85ffb
P2860
A phase 2 trial of dacomitinib (PF-00299804), an oral, irreversible pan-HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non-small cell lung cancer after failure of prior chemotherapy and erlotinib.